Patent · US Active

Influenza virus vector for virotherapy

US10480013B2 · kind B2 · utility

0Cited by

0References

14Claims

0Family size

Assignee

BLUE SKY VACCINES GMBH · AT

Inventors

Thomas Muster · Wien, AT
Markus Wolschek · Wien, AT

Key dates

Filing date	Oct 16, 2018
Grant date	Nov 19, 2019
Priority date	—
Expiry date	Oct 16, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/16162
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a recombinant influenza virus vector comprising an NS gene encoding a truncated NS1 protein of at least 73 and up to 122 amino acids of the N-terminus of the respective wild type NS1 protein, wherein the vector replicates in IFN-sensitive tumor cells and does not replicate in normal, non-tumor cells, and expresses a heterologous immunostimulatory polypetide. The invention further provides a pharmaceutical composition containing the influenza virus vector, its use for the treatment of cancer patients and methods for producing the influenza virus vaccine.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.